We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
AT&T
T
$162B
| $7.78M | 0.17% |
340,355
+153,753
| +82% | +$3.4M |
|
152
NetEase
NTES
$84.2B
| $7.76M | 0.17% |
+75,159
| New | +$8.51M |
|
153
Cardinal Health
CAH
$55.2B
| $7.7M | 0.17% |
126,727
-423,492
| -77% | -$23.4M |
|
|
RACB
154
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $7.69M | 0.17% |
+750,000
| New | +$7.68M |
|
155
News Corp Class A
NWSA
$15.1B
| $7.59M | 0.17% |
+298,477
| New | +$6.69M |
|
156
Charter Communications
CHTR
$17.2B
| $7.56M | 0.17% |
+12,246
| New | +$7.65M |
|
|
MAACU
157
DELISTED
Montes Archimedes Acquisition Corp. Unit
MAACU
| $7.42M | 0.16% |
727,794
-278,658
| -28% | -$3M |
|
158
PMV Pharmaceuticals
PMVP
$59.7M
| $7.36M | 0.16% |
223,690
-1,131
| -0.5% | -$44.6K |
|
|
APLS
159
DELISTED
Apellis Pharmaceuticals
APLS
| $7.36M | 0.16% |
+171,419
| New | +$8.11M |
|
160
Monster Beverage
MNST
$91.5B
| $7.11M | 0.16% |
156,142
-4,894
| -3% | -$219K |
|
|
XLRN
161
DELISTED
Acceleron Pharma
XLRN
| $7.11M | 0.16% |
+52,417
| New | +$6.77M |
|
|
SGEN
162
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.07M | 0.16% |
50,887
+1,090
| +2% | +$176K |
|
|
CMPS
163
Compass Pathways
CMPS
$1.52B
| $7.01M | 0.16% |
190,437
+141,026
| +285% | +$6.18M |
|
164
Scholar Rock
SRRK
$5.49B
| $6.99M | 0.16% |
137,917
+1,459
| +1% | +$80.7K |
|
165
Insulet
PODD
$11.8B
| $6.85M | 0.15% |
+26,246
| New | +$7.03M |
|
166
IDEAYA Biosciences
IDYA
$3.41B
| $6.81M | 0.15% |
+289,949
| New | +$5.6M |
|
167
Immatics
IMTX
$1.23B
| $6.72M | 0.15% |
599,653
+88,397
| +17% | +$1M |
|
168
Option Care Health
OPCH
$3.55B
| $6.57M | 0.15% |
+370,391
| New | +$6.94M |
|
169
Forte Biosciences
FBRX
$1.57B
| $6.52M | 0.14% |
7,613
-78
| -1% | -$63.9K |
|
170
Zentalis Pharmaceuticals
ZNTL
$331M
| $6.25M | 0.14% |
144,161
+4,161
| +3% | +$179K |
|
|
STKL
171
DELISTED
SunOpta
STKL
| $6.21M | 0.14% |
+420,336
| New | +$6.02M |
|
172
Flex
FLEX
$43.4B
| $6.03M | 0.13% |
+436,761
| New | +$6.02M |
|
173
UnitedHealth
UNH
$377B
| $6.02M | 0.13% |
16,173
-35,888
| -69% | -$12.4M |
|
174
Netflix
NFLX
$305B
| $5.97M | 0.13% |
114,430
-212,540
| -65% | -$11.3M |
|
|
AGGRU
175
DELISTED
Agile Growth Corp Units
AGGRU
| $5.96M | 0.13% |
+599,999
| New | +$5.95M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.